Patient characteristics at baseline and weight loss in the first 3 months on a GLP-1 drug were tied to weight-loss outcomes ...
When two experts were asked to discuss JAK inhibitors relative to biologics in the management of moderate-to-severe atopic dermatitis, they agreed each choice has a clinical context.
Results from the phase 3 REDFINE 9 trial show that a lower dose of CagriSema is superior to placebo, which could give clinicians more flexibility with treatment.
After a GLP-1, what works next? Among more than 20,000 patients, surgery was linked to the most weight loss, quitting cold the least, and switching from semaglutide to tirzepatide beat staying put.
Adding online support to tirzepatide was projected to lead to greater health gains than the drug alone, assuming no extra cost, in a UK model of adults with obesity.
The organization says that being forced to practice against moral beliefs and professional obligations is a significant ...
Claims data miss patients who pay cash. A new survey that included these patients found out-of-pocket costs higher than $50 a month predicted GLP-1 discontinuation better than vomiting.
Bulevirtide use in patients with hepatitis D-related cirrhosis is linked with less liver decompensation over 3 years, but its ...
A review of 11 studies suggests endometriosis may take a cumulative toll on work, but long-term data are scarce.
Older adults with hoarding disorder and low income have higher a risk for functional and mild cognitive impairment, a study ...
Dapagliflozin may improve ascites control in patients with cirrhosis and refractory ascites and reduce the need for ...
At the recent Diabetes Technology Meeting, industry representatives shared updates on recently launched products and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results